🇺🇸 FDA
Pipeline program

Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

PRODIGE 118-PEHRICCA

Phase 3 small_molecule active

Quick answer

Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion. for Hihg risk of cholangiocarcinoma intra hépatic resectable is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
Hihg risk of cholangiocarcinoma intra hépatic resectable
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials